Notice of Proposed Sale · 144
Maze Therapeutics, Inc.
MAZENASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- MAZE THERAPEUTICS INC
- Issuer CIK
- 0001842295
- SEC file number
- 001-42490
- Phone
- 650-850-5070
- Person for whose account securities are to be sold
- HAROLD BERNSTEIN
- Relationships to issuer
- Officer
- Street
- 171 Oyster Point Blvd
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 16,141 | 438,712.38 | 55,549,168 | 10/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Exercise of Stock Options | Issuer | 16,141 | N | 10/01/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for HAROLD BERNSTEIN | Common | 09/04/2026 | 9,705 | 254,501.98 |
| 10b5-1 Sales for HAROLD BERNSTEIN | Common | 09/01/2026 | 16,141 | 425,512.27 |
| HAROLD BERNSTEIN | Common | 09/01/2026 | 10,295 | 270,110.94 |
| 10b5-1 Sales for HAROLD BERNSTEIN | Common | 08/13/2026 | 16,142 | 445,620.09 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for HAROLD BERNSTEIN
- Street
- 171 Oyster Point Blvd
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for HAROLD BERNSTEIN
- Street
- 171 Oyster Point Blvd
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 3, entry 1
- Name
- HAROLD BERNSTEIN
- Street
- 171 Oyster Point Blvd
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Seller — prior-sale row 4, entry 1
- Name
- 10b5-1 Sales for HAROLD BERNSTEIN
- Street
- 171 Oyster Point Blvd
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ Harold Bernstein
- Plan adoption dates
- 09/29/2025
Company context
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.